Best Wichita Grants for Nonprofits in Kansas

Hilcorp Future Leaders of America Scholarship

Benefiting select communities across the United States where Hilcorp operates.

The Hilcorp Future Leaders of America Scholarship Program was developed to give back to the communities in which Hilcorp Energy Company operates to develop future leadership talent as the next innovators, educators, and business leaders.

Award Amount

Multiple scholarships awarded annually. The scholarship is comprised of up to four (4) annual awards of $2,500, for a total award of up to $10,000.

The four annual (4) awards may be received over a period of up to 6 years, allowing for deferment if needed.

GBA1 Parkinson's Disease Research Catalyst Program

The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis- driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community.

Funding

Duration: 12 to 24 months

Award Amount: Up to $300,000. Requested support should be commensurate with work proposed.

These budgets include direct and indirect costs. For academic and for-profit institutions, no more than 15% or 10%, respectively, may go to indirect costs. 

Patrick J. Kiley / Houston AGC Scholarship

Benefiting employees, dependents of employees, and/or interns of AGC Houston member firms OR students involved in AGC Student Chapters.

Award Amounts

Multiple awards are given each year. Scholarship award amounts will vary for each selected scholarship recipient.

Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach

Alopecia Areata (AA) is a chronic, immune-mediated condition causing nonscarring hair loss that affects about 2% of the global population and can lead to substantial psychosocial burden if disease is severe and untreated. The treatment landscape has recently evolved with the approval of ritlecitinib, a systemic therapy for severe AA in adults and adolescents aged 12 years and older, based on efficacy demonstrated in the ALLEGRO phase 2b/3 program.

Despite this advance, important questions remain regarding the optimal timing of therapy initiation. Emerging post-hoc analyses from the ALLEGRO program indicate that patients with shorter disease duration and lower baseline severity achieve higher response rates, suggesting that earlier intervention with ritlecitinib may lead to improved outcomes.

Geographic Scope

United States 

Funding Range and Project Length

Individual projects requesting up to $100,000 USD will be considered.

Maximum project length is 24 months.

Hemophilia Fellowship

This competitive grant program seeks to support an institution-based fellowship that emphasizes shared decision making (SDM), patient education, and multidisciplinary team-based care. The intent is to strengthen the hemophilia care through equitable education, and patient-centered shared decision making in a rapidly evolving treatment landscape.

Geographic Scope

• United States 

Funding Range and Project Length

• Grant funding is available to support a one year fellowship up to $100.000 USD. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years. 

OREF/Musculoskeletal Transplant Foundation Research Grant

Solicits investigator-initiated proposals focusing on research in the science of biologic – reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation.